Covaxin has inched a step closer to a WHO emergency use listing. The global body has accepted Bharat Biotech’s expression of interest (EoI) for the inactivated vaccine. The pre-submission meeting with WHO officials is now planned for June 23. Covaxin’s dossier would be taken up for review only after the company submits the entire phase-3 clinical trials data. An interim analysis of Covaxin’s Phase-3 trials had indicated an overall efficacy of 78%. Bharat Biotech is now conducting a phase-3 study on 4,500 volunteers in Brazil.